Clinical Trial Update: Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML [Phase 1]

View source ↗

Summary

The Phase 1 trial of LAVA-051 in relapsed/refractory Chronic Lymphocytic Leukemia, Multiple Myeloma, or Acute Myeloid Leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Multiple Myeloma

Drugs mentioned

• LAVA-051

Snippet

Sponsor: Lava Therapeutics | Conditions: Chronic Lymphocytic Leukemia, Multiple Myeloma | Phase 1 | Status: TERMINATED